Needham Upgrades Rocket Pharmaceuticals After FDA Clears Path for Danon Gene Therapy Trial

FDA let Rocket keep its 12-patient Danon study and count the first 3 patients. Needham upgraded RCKT and removed a key regulatory overhang.